Related Experiment Video
Updated: Aug 29, 2026
Application of Robot-assisted Pancreaticobiliary Junction Resection in Benign Duodenal Tumors
Published on: December 20, 2024
Bile Duct-Narrowing Neuroendocrine Tumors Show a PDX1+/CDX2+ Phenotype Resembling Duodenal Rather Than Pancreatic
Atsuko Kasajima1, Ayako Ura1, Katja Evert2
1Department of Pathology, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany; Bavarian Center for Cancer Research (BZKF), Munich, Germany.
Abstract:
Neuroendocrine tumors (NETs) associated with the intrapancreatic bile duct are rare and poorly characterized. Their relationship to conventional pancreatic NETs and to neuroendocrine cells of the periampullary and peribiliary regions remains unclear. A total of 199 resected NETs from the pancreas were evaluated for anatomical location and intrapancreatic bile duct narrowing. Transcription factor and hormone expression were assessed by whole-slide immunohistochemistry. For comparison, 22 duodenal NETs (DuoNETs), 6 ampullary NETs, and nonneoplastic duodenal, ampullary, and bile duct tissues were examined. Nineteen tumors (10%) were associated with bile duct narrowing, including 11 lower (periampullary) and 8 upper bile duct lesions. Compared with NETs without bile duct narrowing, these tumors were exclusively nonfunctioning, occurred more frequently in women, and exhibited higher Ki-67 indices. Lower bile duct-narrowing tumors were associated with shorter progression-free survival. All but one bile duct-narrowing tumor expressed PDX1 (18/19, 95%), whereas CDX2 expression was observed in 73% (8/11) of lower bile duct-narrowing tumors. These tumors frequently expressed gastrin (73%) and somatostatin (73%), occasionally serotonin (27%), and lacked glucagon and insulin expression. Their transcription factor and hormone expression profiles closely resembled those of DuoNETs and neuroendocrine cells of the periampullary and peribiliary glands and differed from those of conventional pancreatic NETs. Bile duct-narrowing NETs from the pancreas, particularly those involving the lower bile duct, represent a distinct clinicopathological subgroup characterized by a PDX1-positive, frequently CDX2-positive phenotype and enrichment for gastrin and somatostatin expression. Their resemblance to DuoNETs and periampullary/peribiliary neuroendocrine cells supports a shared differentiation program and suggests a possible nonislet cell origin.
